(Q34816825)

English

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Guru Sonpavde

1

1 reference

Europe PubMed Central

4 August 2017

Bryan H Goldman

2

1 reference

Europe PubMed Central

4 August 2017

V O Speights

3

1 reference

Europe PubMed Central

4 August 2017

Seth P Lerner

4

1 reference

Europe PubMed Central

4 August 2017

David P Wood

5

1 reference

Europe PubMed Central

4 August 2017

Nicholas J Vogelzang

6

1 reference

Europe PubMed Central

4 August 2017

Donald L Trump

7

1 reference

Europe PubMed Central

4 August 2017

Ronald B Natale

8

1 reference

Europe PubMed Central

4 August 2017

H Barton Grossman

9

1 reference

Europe PubMed Central

4 August 2017

E David Crawford

10

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

1 September 2009

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

115

1 reference

Europe PubMed Central

4 August 2017

18

1 reference

Europe PubMed Central

4 August 2017

4104-4109

1 reference

Europe PubMed Central

4 August 2017

Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Significance of histopathological evaluation in primary therapy for breast cancer--recent trends in primary modality with pathological complete response (pCR) as endpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

8 July 2018

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

26 October 2018

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

26 October 2018

Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

26 October 2018

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

26 October 2018

Surgical factors influence bladder cancer outcomes: a cooperative group report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

26 October 2018

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

26 October 2018

A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079554

26 October 2018

Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19517476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall

1 reference

https://pubmed.ncbi.nlm.nih.gov/19517476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19517476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists

1 reference

https://pubmed.ncbi.nlm.nih.gov/19517476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19517476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19517476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://pubmed.ncbi.nlm.nih.gov/19517476

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.24466

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34816825&oldid=1592779625"